drugset
drugset / Trial / NCT03608319

Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled Conditions

NCT03608319 ↗

Phase 1 Completed 17 enrolled Albireo Celerion · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of this study is to determine the single-dose pharmacokinetics (PK) of A4250 when administered after a high-fat meal and when sprinkled on applesauce in healthy adult subjects.

Timeline

Start
2018-07-05
Primary completion
2018-08-05
Completion
2018-08-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Odevixibat Small molecule 9.6 mg Oral

Indications

No indication recorded.